CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer

161O Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib

(2020) M. Arnedos et al.   ANNALS OF ONCOLOGY

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

(2019) George W. Sledge et al.   JAMA Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis

(2018) Hadar Goldvaser et al.   CANCER TREATMENT REVIEWS

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical utility of gene-expression signatures in early stage breast cancer

(2017) Maryann Kwa et al.   Nature Reviews Clinical Oncology

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Breast Cancer Tumor Size, Nodal Status, and Prognosis: Biology Trumps Anatomy

(2011) Elizabeth A. Comen et al.   JOURNAL OF CLINICAL ONCOLOGY